Skip to main content
MedPathMedPath Home
Clinical Trials/NCT03764917
NCT03764917
Unknown
Not Applicable

Study on the Effect of NGS Combined With RNAseq on Tumor Immune Escape in Advanced Non-small Cell Lung Cancer EGFR and ALK Mutant Negative Patients

Shanghai Pulmonary Hospital, Shanghai, China1 site in 1 country100 target enrollmentDecember 1, 2018
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsNon-small Cell Lung Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Non-small Cell Lung Cancer
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Enrollment
100
Locations
1
Primary Endpoint
numbers of immune cells
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

Study on the tumor immune escape in advanced non-small cell lung cancer patients with EGFR and ALK mutant negative by NGS combined with RNAseq

Detailed Description

Study on the tumor immune escape in advanced non-small cell lung cancer patients with EGFR and ALK mutant negative by NGS combined with RNAseq. Detecting non-small cell lung cancer patient NGS and RNAseq data before first-line chemotherapy, after two cycles chemotherapy and after disease progression.

Registry
clinicaltrials.gov
Start Date
December 1, 2018
End Date
December 31, 2021
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Responsible Party
Principal Investigator
Principal Investigator

Caicun Zhou

Prof. Caicun Zhou

Shanghai Pulmonary Hospital, Shanghai, China

Eligibility Criteria

Inclusion Criteria

  • •Non-small cell lung cancer patient First-line chemotherapy with platinum-based chemotherapy

Exclusion Criteria

  • •EGFR mutant positive Alk mutant positive

Outcomes

Primary Outcomes

numbers of immune cells

Time Frame: 24 months

detecting numbers of immune cells before first-line chemotherapy, after two cycles chemotherapy and after disease progression

Secondary Outcomes

  • numbers of tumor mutations(24 months)

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
K-RAS and EGFR in Lung CancerNon Small Cell Lung Cancer
NCT03951233Hellenic Cooperative Oncology Group424
Terminated
Not Applicable
A Study to Assess the Survival of Non-small Cell Lung Cancer Patients Treated With Tarceva After Failed Chemotherapy TreatmentNon-Squamous Non-Small Cell Lung Cancer
NCT01990261Hoffmann-La Roche33
Active, not recruiting
Phase 1
Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)Metastatic Non Small Cell Lung Cancer
NCT04743505Washington University School of Medicine27
Completed
Phase 1
Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)Advanced Non Small Cell Lung CancerAdvanced (Inoperable) Non Small Cell Lung Cancer
NCT02157883AstraZeneca39
Not yet recruiting
Not Applicable
The Clinical Characteristics and Efficacy of Immunotherapy in First-line PD-L1-negative Advanced NSCLC PatientsNSCLC
NCT06496009Shanghai Pulmonary Hospital, Shanghai, China845